Posted inStock
Teva stock soars on positive Phase 2b study results
Investing.com — Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) surged 17% following the announcement of successful Phase 2b study results for its investigational drug duvakitug, which is being developed to…